Trending...
- Southern Soul Artist Moe Z Releases New Single 'Set It Out' Distributed by Morris Day Entertainment
- Cal State LA secures funding for two artificial intelligence projects from CSU
- Skool Alternatives Reddit: Skool vs Circle vs Whop - Did you join one yet?
SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company's board of directors.
"Christine has an impressive track record of leading both private and public biotechnology companies through critical value-creating inflection points, and we are excited to welcome her to our board of directors," said Jeffrey Hatfield, chief executive officer of Vividion. "As Vividion continues to make progress building a company and pipeline aimed at delivering precision therapeutics for cancer and immune disorders, we look forward to leveraging her wealth of experience and unique perspectives across pipeline development, business operations, corporate strategy and growth."
More on The Californer
"Vividion has made tremendous advancements over the last several years, and today, the company stands in a strong position to begin realizing the value of that work," said Ms. Siu. "I am impressed by the experienced team assembled and the science and proprietary approach aimed at addressing traditionally undruggable targets to develop therapies for patients with critical unmet needs. I look forward to partnering with the management team and board of directors to help advance the company's deep and diversified pipeline."
Ms. Siu brings a strong track record of creating value and integrating financing strategy with corporate development to the Vividion board of directors. Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma, Inc, and former chief financial officer at Eidos Therapeutics, Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures, where she was part of the GBT launch team and first employee at GBT. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.
More on The Californer
About Vividion
Vividion Therapeutics, Inc. is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company's platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.
"Christine has an impressive track record of leading both private and public biotechnology companies through critical value-creating inflection points, and we are excited to welcome her to our board of directors," said Jeffrey Hatfield, chief executive officer of Vividion. "As Vividion continues to make progress building a company and pipeline aimed at delivering precision therapeutics for cancer and immune disorders, we look forward to leveraging her wealth of experience and unique perspectives across pipeline development, business operations, corporate strategy and growth."
More on The Californer
- Yvette Kendall Secures $6 Million Deal with The Sessions Studios for Horror Thriller, "NORTH"
- Buy The Crave Launches Premium Creatine and Natural Wellness Supplements for Modern Lifestyles
- Long Beach Parks, Recreation and Marine's Homeland Cultural Center Presents DanceFest at Cesar Chavez Park Amphitheater on August 16
- Sisu, a Portrait of Grit, Connection and Triumph, Premieres on Documentary Showcase
- New Liz Taylor Book Coming Soon: Chasing Elizabeth Taylor
"Vividion has made tremendous advancements over the last several years, and today, the company stands in a strong position to begin realizing the value of that work," said Ms. Siu. "I am impressed by the experienced team assembled and the science and proprietary approach aimed at addressing traditionally undruggable targets to develop therapies for patients with critical unmet needs. I look forward to partnering with the management team and board of directors to help advance the company's deep and diversified pipeline."
Ms. Siu brings a strong track record of creating value and integrating financing strategy with corporate development to the Vividion board of directors. Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma, Inc, and former chief financial officer at Eidos Therapeutics, Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures, where she was part of the GBT launch team and first employee at GBT. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.
More on The Californer
- City of Long Beach Experienced a 4% Decrease in Fireworks-Related Reports on July 4
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Wise Business Plans Launches Turnkey Startup Packages to Help Entrepreneurs Start and Scale
- CarSeek Re-Launch: A New Look, A Better Experience for Car Buyers
- California: Governor Newsom provides $11 million to organizations helping underserved job seekers find training and employment
About Vividion
Vividion Therapeutics, Inc. is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company's platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.
Filed Under: Business
0 Comments
Latest on The Californer
- First Partner highlights apprenticeship program helping underrepresented youth break into careers in California's iconic entertainment industry
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Cal State LA secures funding for two artificial intelligence projects from CSU
- Colbert Packaging Announces WBENC Recognition
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Over the past three months, California seized $476 million worth of unlicensed cannabis products
- California scores more clean energy records: 9 in 10 days this year partially powered by 100% clean energy
- "Mobile Suit Gundam" Takes Over San Diego Comic-Con 2025
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Hamilton Zanze Sponsors the Acquisition of Two Garden-Style Communities in Reno Area
- Meet a Scientologist Captures Greece's Timeless Beauty with Videographer Lambros Malamas
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
- Moovs Launches Advanced Contact Center Solution for Large-Scale Transportation Operations
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Second Annual Artists' Rights Advocate Award to Be Presented at The Comedy Store on July 17th
- Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Ship Overseas Inc. Expands Specialized Shipping Services